Paricalcitol Generics Suppliers & Bulk Manufacturers
Available Forms: Capsules and Injection
Available Strengths: Capsules:1mcg, 2mcg, 4 mcg & Injection: 2mcg/mL , 5mcg/mL
Reference Brands: Zemplar®(US &EU)
Category:
Nephrology
Paricalcitol (Zemplar®) is a selective vitamin D receptor activator used to manage secondary hyperparathyroidism in CKD patients, available as oral capsules and IV injection. Approved in both the EU and US, it offers targeted PTH control with a lower risk of hypercalcemia and hyperphosphatemia. Suitable for hospital tenders, licensing, and distribution in the global renal care market.
Paricalcitol Generics is available in Capsules and Injection
and strengths such as Capsules:1mcg, 2mcg, 4 mcg & Injection: 2mcg/mL , 5mcg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Paricalcitol Generics is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Paricalcitol Generics can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Paricalcitol, marketed as Zemplar®, is a selective vitamin D receptor activator used to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD), both on dialysis (stage 5) and in pre-dialysis stages (3–4). It effectively lowers parathyroid hormone (PTH) levels while minimizing the risk of hypercalcemia and hyperphosphatemia. Available as oral capsules (1 mcg, 2 mcg, 4 mcg) and IV injection (2 mcg/mL, 5 mcg/mL), Paricalcitol is approved in both the US (FDA) and EU (EMA). It is a key therapeutic in nephrology and an excellent B2B opportunity for licensing, distribution, and hospital-based partnerships in regulated markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing